June 9, 2017

Top-line data from this study remains on track to report in September 2017 Devon, PA (GLOBE NEWSWIRE) – Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to developing and commercializing innovative transdermal synthetic cannabinoid treatments, today announced that it has met its enrollment target of 16 patients in its Phase 2 FAB-C (Treatment […]

Medical marijuana is legal in 26 states, the District of Columbia and Guam. Proponents of marijuana, backed by several studies, say the drug has many therapeutic uses. Opponents — and the U.S. government — however, say it has a high potential for abuse and no legitimate therapeutic value. Marijuana’s medicinal uses can be traced back […]

A large clinical trial conducted on a drug derived from cannabis has demonstrated reduction of convulsive seizures experienced by children with a severe form of epilepsy by nearly 50%[1]. The results, published in the New England Journal of Medicine (online, 25 May 2017), has generated interest from the mainstream media. The multicentre international trial randomised 120 […]

DEVON, Pa., June 08, 2017 (GLOBE NEWSWIRE) — Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to developing and commercializing innovative transdermal synthetic cannabinoid treatments, today announced that it has met its enrollment target of 16 patients in its Phase 2 FAB-C (Treatment of Fragile X Syndrome Anxiety and Behavioral Challenges with CBD) […]